Berwyn, Pa., April 8, 2015/PRNewswire/ — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced that it was issued U.S. Patent No. 8,691,864, “Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia” by the U.S. Patent and Trademark Office. The “864 patent covers use of Posiphen and analogs to treat dementia.
The claims extend and broaden QR’s protection for the composition of matter of Posiphen and pharmaceutical compositions containing Posiphen as well as for methods of treating Alzheimer’s disease and other neurodegenerative disorders.
About QR Pharma
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs: Posiphen for early stage Alzheimer’s and Parkinson’s Disease, and BNC for advanced AD.
QR has successfully completed Phase I clinical trials with Posiphen and is conducting other clinical and pre-clinical work in Traumatic Brain Injury (TBI) for the US Army. QR has recently been chosen for a human trial in Alzheimer’s patients in a NIH sponsored clinical trial.
Forward-Looking Statements
Certain statements in this press release made by management are “forward-looking statements”, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements.
For more information on QR Pharma, please visit the company’s website, http://www.qrpharma.wbprg.pw.
Contact: Maria L. Maccecchini, CEO
Tel: 610 727 3710
maccecchini@qrpharma.com
http://qrpharma.wbprg.pw